XNASMGRM
Market cap85mUSD
Jan 10, Last price
2.50USD
1D
0.00%
1Q
4.17%
IPO
-81.48%
Name
Monogram Orthopaedics Inc
Chart & Performance
P/E
—
P/S
235.02
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-6.23%
Rev. gr., 5y
%
Revenues
365k
Net income
-14m
L+0.40%
CFO
-14m
L+60.85%
Profile
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
IPO date
May 18, 2023
Employees
27
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 365 | ||||||
Cost of revenue | 17,633 | 11,000 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (17,268) | (11,000) | |||||
NOPBT Margin | |||||||
Operating Taxes | 3,334 | ||||||
Tax Rate | |||||||
NOPAT | (17,268) | (14,334) | |||||
Net income | (13,745) 0.40% | (13,691) 15.88% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 15,331 | 13,594 | |||||
BB yield | -19.89% | ||||||
| Debt | |||||||
Debt current | 128 | 118 | |||||
Long-term debt | 856 | 1,102 | |||||
Deferred revenue | |||||||
Other long-term liabilities | 1 | ||||||
Net debt | (12,605) | (9,248) | |||||
| Cash flow | |||||||
Cash from operating activities | (13,543) | (8,420) | |||||
CAPEX | (65) | (241) | |||||
Cash from investing activities | (65) | (241) | |||||
Cash from financing activities | 16,728 | 13,594 | |||||
FCF | (17,543) | (14,775) | |||||
| Balance | |||||||
Cash | 13,589 | 10,469 | |||||
Long term investments | |||||||
Excess cash | 13,571 | 10,469 | |||||
Stockholders' equity | (51,477) | (37,745) | |||||
Invested Capital | 65,366 | 42,505 | |||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 22,409 | 29,253 | |||||
Price | 3.44 | ||||||
Market cap | 77,088 | ||||||
EV | 64,483 | ||||||
EBITDA | (16,856) | (10,613) | |||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||